

## **A Sneak Peek at the Upcoming Oral Presentations at RAD, RAA, and ReV**

Lois Levine, MA

With this year's annual Revolutionizing Atopic Dermatitis (**RAD**), Revolutionizing Alopecia Areata (**RAA**), and Revolutionizing Vitiligo (**ReV**) now only days away, here is a sneak peek of several oral presentations you'll find at the conference:

### **At RAD, you'll learn about:**

- The 52-week results from a maximum-use trial on ruxolitinib cream for children aged 2 to 11 years with extensive dermatitis
- An observational study assessing the treatment of conjunctivitis in dupilumab-treated patients with atopic dermatitis
- A post hoc analysis of ARCADIA 1 and 2 data showing fast itch response of nemolizumab in patients with atopic dermatitis

### **At RAA, dig deep into:**

- The epidemiology of AA, including incidence, lifetime cumulative incidence, point prevalence and lifetime prevalence
- Assessing AA severity, using the SALT tool, assessment of hair, nail and eyebrow/eyelash severity, global assessments and more

### **At ReV, sit in on:**

- Recent advances in devices for vitiligo, including a new excimer treatment for both segmental and non-segmental vitiligo, as well as the latest advances in melanocyte keratinocyte transplant
- What it means to have excellence in vitiligo clinical practice, including set-up, devices, prescribing habits, and more

Register for this year's **RAD, ReV and RAA (RAVE) Conference**, June 8-10, 2024, in Chicago, Illinois. Don't miss out!